Research Analysts’ Recent Ratings Changes for DBV Technologies (DBVT)

A number of research firms have changed their ratings and price targets for DBV Technologies (NASDAQ: DBVT):

• 5/4/2026 – DBV Technologies had its “buy” rating reaffirmed by Guggenheim. They now have a $51.00 price target on the stock.
• 5/2/2026 – DBV Technologies was upgraded by Wall Street Zen from “sell” to “hold”.
• 5/1/2026 – DBV Technologies had its “outperform” rating reaffirmed by Citigroup Inc..
• 5/1/2026 – DBV Technologies had its price target raised by Citizens Jmp from $47.00 to $55.00. They now have a “market outperform” rating on the stock.
• 3/28/2026 – DBV Technologies was downgraded by Wall Street Zen from “hold” to “sell”.
• 3/27/2026 – DBV Technologies had its price target raised by Citizens Jmp from $45.00 to $47.00. They now have a “market outperform” rating on the stock.
• 3/27/2026 – DBV Technologies had its “buy” rating reaffirmed by Guggenheim. They now have a $51.00 price target on the stock.

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.